MK-8353 is primarily investigated for its potential in cancer treatment, particularly as an inhibitor of the ERK signaling pathway, which is often dysregulated in various cancers. By targeting this pathway, it aims to hinder tumor growth and proliferation, showing promise in preclinical studies for cancers like melanoma, colorectal cancer, and non-small cell lung cancer. Its application extends to combination therapies, where it is studied alongside other targeted agents or immunotherapies to enhance efficacy and overcome resistance. Ongoing clinical trials are evaluating its safety, tolerability, and effectiveness in patients with advanced solid tumors.